ASCO 2023 | Management of premenopausal HR+/HER2- breast cancer with micro-metastasis

Nadeem Bilani, MD, Icahn School of Medicine at Mount Sinai, New York, NY, provides an overview of survival outcomes in premenopausal patients with HR+/HER2- breast cancer and lymph node micro-metastasis. There is no consensus on the treatment strategy for patients with micro-metastasis, despite chemotherapy being recommended in patients with 1-3 lymph nodes. Evaluation of data from the National Cancer Database (NCDB) revealed that whilst addition of chemotherapy to endocrine therapy was beneficial in patients with a recurrence score of less than 26 involving 1-3 lymph nodes, patients with micro-metastatic disease had no survival advantage. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.